Industry leaders explored the risks and benefits of adopting a China Plus One strategy at Advamed’s The MedTech Conference in ...
On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating ...
Abbott Laboratories raised its 2024 earnings guidance after strong Q3 results, driven by growth in Pharma and MedTech ...
JNJ's 3Q earnings expected to be $2.21 EPS and $22.16B revenue. Recent acquisitions and drug trials impacting stock's ...
Here are eight key developments from spine and orthopedic devicemakers since Oct. 9. 1. Johnson & Johnson MedTech began the ...
Authors:Kirk Harmon, Vice President & GM, Contract Sales Organization, IQVIAJavier “Jave” Castillo, R.Ph, Vice President, CSO ...
Employees at the 10 largest medtech employers in the world are excited about culture but are still frustrated by corporate ...
Focus on international early-stage and pre-commercial biotech & medtech opportunities ...
Our 2024 Women in Medtech edition features insights from Abbott's Lisa Earnhardt, Medtronic's Nina Goodheart, and more.
Event puts focus on medical technologies Oct. 15-17 at the Metro Toronto Convention Centre ...
Johnson & Johnson beat investors’ expectations despite its medtech unit underperforming, with execs pointing to the Asia-Pacific region as a continued source of struggle. Executives said on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback